Pfizer, Roivant unveil Priovant with high potential TYK2/JAK1 inhibitor Business, R&D Pfizer and Roivant Sciences unveiled a new company called Priovant Therapeutics to develop and market new therapies for a wide range of autoimmune diseases with high mortality and morbidity rates. Read more June 28, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/01/Anticipating-a-Permanent-Shift-to-Virtual-Pfizer-will-Reduce-Sales-Reps-BioSpace-1-12-22.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-06-28 11:26:492022-06-28 11:26:49Pfizer, Roivant unveil Priovant with high potential TYK2/JAK1 inhibitor